System and method for correction of acquired transaction text fields von Rozenblum, Rotem, Shahar, Shimon, Horesh, Yair, Resheff, Yehezkel S

Volltext bestellen

SYSTEM AND METHOD FOR CORRECTION OF ACQUIRED TRANSACTION TEXT FIELDS von Rozenblum, Rotem, Shahar, Shimon, Horesh, Yair, Resheff, Yehezkel S

Volltext bestellen

System and method for correction of acquired transaction text fields von Rozenblum, Rotem, Shahar, Shimon, Horesh, Yair, Resheff, Yehezkel S

Volltext bestellen

A multi-center international study on the spinal cord independence measure, version IV: Rasch psychometric validation von Catz, Amiram, Itzkovich, Malka, Rozenblum, Rotem, Elkayam, Keren, Kfir, Adi, Tesio, Luigi, Chhabra, Harvinder Singh, Michaeli, Dianne, Zeilig, Gabi, Engel-Haber, Einat, Bizzarini, Emiliana, Pilati, Claudio, Stigliano, Salvatore, Merafina, Marcella, Del Popolo, Giulio, Righi, Gabriele, Bonavita, Jacopo, Baroncini, Ilaria, Liu, Nan, Xing, Huayi, Margalho, Paulo, Campos, Ines, Riberto, Marcelo, Soeira, Thabata Pasquini, Chandy, Bobeena, Tharion, George, Joshi, Mrinal, Lemay, Jean-François, Laramée, Marie-Thérèse, Curran, Dorothyann, Leiulfsrud, Annelie Schedin, Sørensen, Linda, Biering-Sorensen, Fin, Poder, Henrik Hagen, Kesiktas, Nur, Burgess-Collins, Lisa, Edwards, Jayne, Osman, Aheed, Bluvshtein, Vadim

Volltext bestellen

The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer von Laufer-Geva, Smadar, Rozenblum, Anna Belilovski, Twito, Tal, Grinberg, Roxana, Dvir, Addie, Soussan-Gutman, Lior, Ilouze, Maya, Roisman, Laila C., Dudnik, Elizabeth, Zer, Alona, Rotem, Ofer, Lanman, Richard B., Peled, Nir

Volltext

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi) von Dudnik, Elizabeth, Bshara, Elias, Grubstein, Ahuva, Fridel, Ludmila, Shochat, Tzippy, Roisman, Laila C., Ilouze, Maya, Rozenblum, Anna Belilovski, Geva, Smadar, Zer, Alona, Rotem, Ofer, Allen, Aaron M., Peled, Nir

Volltext

145P Impact of next-generation sequencing on survival in lung cancer von Geva, S., Belilovski Rozenblum, A., Roisman, L.C., Ilouze, M., Dudnik, E., Zer, A., Rotem, O., Peled, N.

Volltext

Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study von Gillis, R., Peled, N., Goldshtien, I., Rotem, O., Rozenblum, A.B., Nechushtan, H., Chen, L., Dudnik, E., Zer, A., Yust-Katz, S., Shelef, I., Roisman, L.C., Inbar, E.

Volltext

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study von Peled, Nir, Kian, Waleed, Inbar, Edna, Goldstein, Iris M, Zemel, Melanie, Rotem, Ofer, Rozenblum, Anna B, Nechushtan, Hovav, Dudnik, Elizabeth, Levin, Daniel, Zer, Alona, Keren-Rosenberg, Shoshana, Yust-Katz, Shlomit, Fuchs, Vered, Remilah, Areen A, Shelef, Ilan, Roisman, Laila C

Volltext

Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi) von Dudnik, Elizabeth, Bshara, Elias, Grubstein, Ahuva, Fridel, Ludmila, Shochat, Tzippy, Roisman, Laila C, Ilouze, Maya, Rozenblum, Anna B, Geva, Smadar, Zer, Alona, Rotem, Ofer, Allen, Aaron, Peled, Nir

Volltext

P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study von Peled, N., Rotem, O., Rozenblum, A., Nechushtan, H., Chen, L., Dudnik, E., Zer, A., Yust-Katz, S., Shelef, I., Roisman, L., Inbar, E.

Volltext

P3.01-28 The Clinical Impact of Comprehensive cfDNA Genomic Testing in Lung Cancer von Geva, S., Belilovski Rozenblum, A., Twito, T., Grinberg, R., Dvir, A., Soussan Gutman, L., Roisman, L., Ilouze, M., Dudnik, E., Zer, A., Rotem, O., Lanman, R., Peled, N.

Volltext

146P The clinical impact of comprehensive cfDNA genomic testing in lung cancer von Geva, S., Rozenblum, A. Belilovski, Grinberg, R., Dvir, A., Soussan-Gutman, L., Roisman, L.C., Dudnik, E., Zer, A., Rotem, O., Peled, N.

Volltext

Impact of next-generation sequencing on survival in lung cancer: 145P von Geva, S, Rozenblum, Belilovski A, Roisman, L C, Ilouze, M, Dudnik, E, Zer, A, Rotem, O, Peled, N

Volltext

The clinical impact of comprehensive cfDNA genomic testing in lung cancer: 146P von Geva, S, Rozenblum, Belilovski A, Grinberg, R, Dvir, A, Soussan-Gutman, L, Roisman, L C, Dudnik, E, Zer, A, Rotem, O, Peled, N

Volltext